{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:32:32Z","timestamp":1764952352330,"version":"3.46.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clinre.2025.102733","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:07:15Z","timestamp":1763658435000},"page":"102733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and economic outcomes of adding durvalumab to gemcitabine\/cisplatin in advanced biliary tract cancers: A multicenter descriptive study"],"prefix":"10.1016","volume":"49","author":[{"given":"Lena","family":"Luciani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9onie","family":"Leuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Clarenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violaine","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elia","family":"Gigante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-7034","authenticated-orcid":false,"given":"Florian","family":"Slimano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clinre.2025.102733_bib0001","first-page":"e583","article-title":"Differences in cancer rates among adults born between 1920 and 1990 in the USA: analysis of population-based cancer registry data","volume":"9","author":"Sung","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2025.102733_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114000","article-title":"Biliary tract cancers: french national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","volume":"202","author":"Roth","year":"2024","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clinre.2025.102733_bib0003","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J Hepatol"},{"issue":"14","key":"10.1016\/j.clinre.2025.102733_bib0004","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clinre.2025.102733_bib0005","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/cells12162098","article-title":"Lacking immunotherapy biomarkers for biliary tract cancer: a comprehensive systematic literature review and meta-analysis","volume":"12","author":"Frega","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.clinre.2025.102733_bib0006","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102733_bib0007","article-title":"Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC)","author":"Ioka","year":"2019","journal-title":"J Clin Oncol 2019 [abstract]"},{"issue":"8","key":"10.1016\/j.clinre.2025.102733_bib0008","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"author":"Autorit\u00e9 de Sant\u00e9","key":"10.1016\/j.clinre.2025.102733_bib0009"},{"author":"Autorit\u00e9 de Sant\u00e9","key":"10.1016\/j.clinre.2025.102733_bib0010"},{"issue":"8","key":"10.1016\/j.clinre.2025.102733_bib0011","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2025.102733_bib0012","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clinre.2025.102733_bib0013","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S1470-2045(24)00134-7","article-title":"Dose selection of novel anticancer drugs: exposing the gap between selected and required doses","volume":"25","author":"Hoog","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102733_bib0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2025.102733_bib0016","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00280-024-04697-x","article-title":"Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer","volume":"94","author":"Gandhi","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102733_bib0017","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.clinre.2025.102733_bib0018","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO-24-02347","article-title":"De-escalation strategies with immune checkpoint blockers in non-small cell lung cancer: do we already have enough evidence?","volume":"43","author":"Remon","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2025.102733_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274532","article-title":"Integrating treatment cost reduction strategies and biomarker research to reduce costs and personalize expensive treatments: an example of a self-funding trial in non-small cell lung cancer","volume":"14","author":"Buma","year":"2023","journal-title":"Front Pharmacol"},{"issue":"35","key":"10.1016\/j.clinre.2025.102733_bib0020","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1016\/j.annonc.2024.08.1315","article-title":"Low dose versus standard dose pembrolizumab for treatment of advanced non-small cell lung carcinoma: results of the pre-planned interim analysis of the NVALT-30 clinical trial","volume":"5","author":"Van den Heuvel","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinre.2025.102733_bib0021","article-title":"Low-dose anti-PD(L)1 for the treatment of solid malignancies","volume":"10","author":"Souza","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.clinre.2025.102733_bib0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12962-023-00429-9","article-title":"Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial","volume":"21","author":"Zhao","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"issue":"10","key":"10.1016\/j.clinre.2025.102733_bib0023","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/liv.15699","article-title":"Immune checkpoint inhibitor for patients with advanced biliary tract cancer: a cost-effectiveness analysis","volume":"43","author":"Zhu","year":"2023","journal-title":"Liver Int"},{"issue":"10391","key":"10.1016\/j.clinre.2025.102733_bib0024","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"journal-title":"online","article-title":"Arr\u00eat\u00e9 du 5 novembre 2024 modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques prises en charge en sus des prestations d'hospitalisation mentionn\u00e9e \u00e0 l'article L. 162-22-7 du code de la s\u00e9curit\u00e9 sociale","year":"2024","key":"10.1016\/j.clinre.2025.102733_bib0025"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125002104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125002104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:30:08Z","timestamp":1764952208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125002104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2210740125002104"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102733","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and economic outcomes of adding durvalumab to gemcitabine\/cisplatin in advanced biliary tract cancers: A multicenter descriptive study","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102733"}}